Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 14742301)

1.

Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD.

Am J Respir Crit Care Med. 2004 May 15;169(10):1103-9. Epub 2004 Jan 23.

PMID:
14742301
2.

Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.

[No authors listed]

Prescrire Int. 2014 Oct;23(153):245-6. Review.

PMID:
25964976
3.

Bedaquiline. More data needed on this dangerous antitubercular drug.

[No authors listed]

Prescrire Int. 2014 Oct;23(153):232-4.

PMID:
25964964
4.

Multidrug resistant tuberculosis.

Millard J, Ugarte-Gil C, Moore DA.

BMJ. 2015 Feb 26;350:h882. doi: 10.1136/bmj.h882. Review. No abstract available.

PMID:
25721508
5.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

6.

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet M, du Cros P, Khamraev AK, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):355-8. doi: 10.1164/rccm.201407-1302LE. No abstract available.

PMID:
25635495
7.

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.

PMID:
25216831
8.

Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.

Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H.

Antimicrob Agents Chemother. 2014 Oct;58(10):6111-5. doi: 10.1128/AAC.03549-14. Epub 2014 Aug 4.

9.

Fluoroquinolone resistance and Mycobacterium tuberculosis: CAP guidelines play an important role.

Goyet S, Vlieghe E, Lim K, van Griensven J, Borand L, Thong P, Rammaert B, Marcy O, Tarantola A.

Int J Tuberc Lung Dis. 2014 May;18(5):628-30. doi: 10.5588/ijtld.13.0922. No abstract available.

PMID:
24903803
10.

Long term outcome of multidrug-resistant TB patients in Fukujuji Hospital in Japan.

Yoshiyama T, Morimoto K, Okumura M, Sasaki Y, Ogata H, Shiraishi Y, Kudou S.

Trans R Soc Trop Med Hyg. 2014 Sep;108(9):589-90. doi: 10.1093/trstmh/tru080. Epub 2014 Jun 5.

PMID:
24902580
11.

Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India.

Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, Oeltmann JE, Moonan PK, Kumar AM.

Ann Am Thorac Soc. 2014 Jun;11(5):712-8. doi: 10.1513/AnnalsATS.201312-447OC.

PMID:
24735096
12.

Multidrug-resistant tuberculosis with fluoroquinolone resistance: sinister association with other drugs and ominous implications for treatment.

Ajbani K, Nikam C, Shetty A, Soman R, Rodrigues C.

Clin Infect Dis. 2014 Jul 1;59(1):138-9. doi: 10.1093/cid/ciu232. Epub 2014 Apr 9. No abstract available.

13.

High prevalence of multidrug resistant tuberculosis in Djibouti: a retrospective study.

Boyer-Cazajous G, Martinaud C, Déhan C, Hassan MO, Gaas Y, Chenilleau-Vidal MC, Soler C.

J Infect Dev Ctries. 2014 Feb 13;8(2):233-6. doi: 10.3855/jidc.3837.

14.

Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis.

Srivastava S, Gumbo T.

Eur Respir J. 2014 Jan;43(1):312-3. doi: 10.1183/09031936.00081313. No abstract available.

15.

Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt?

Yew WW, Lange C.

Int J Tuberc Lung Dis. 2014 Jan;18(1):1-2. doi: 10.5588/ijtld.13.0739. No abstract available.

PMID:
24365543
16.

Risk factors associated with default from multi- and extensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective cohort analysis.

Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z, Khaemraev A, Braker K, Telnov O, du Cros P.

PLoS One. 2013 Nov 6;8(11):e78364. doi: 10.1371/journal.pone.0078364. eCollection 2013.

17.

Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.

Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I.

Euro Surveill. 2013 Oct 3;18(40). pii: 20601.

18.

Weight gain and response to treatment for multidrug-resistant tuberculosis.

Gler MT, Guilatco R, Caoili JC, Ershova J, Cegielski P, Johnson JL.

Am J Trop Med Hyg. 2013 Nov;89(5):943-9. doi: 10.4269/ajtmh.13-0011. Epub 2013 Sep 9.

19.

Salvage therapy for multidrug-resistant tuberculosis.

Seung KJ, Becerra MC, Atwood SS, Alcántara F, Bonilla CA, Mitnick CD.

Clin Microbiol Infect. 2014 May;20(5):441-6. doi: 10.1111/1469-0691.12335. Epub 2013 Aug 30.

20.

Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence].

Yoo JW, Lyu J, Lee SD, Kim WS, Kim DS, Shim TS.

Int J Tuberc Lung Dis. 2013 Sep;17(9):1243-4. doi: 10.5588/ijtld.13.0312. No abstract available.

PMID:
23928173
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk